Introduction

Undifferentiated presentations in the emergency department frequently involve potential drug exposure requiring specialized diagnostic evaluation. Toxicology screening is critical in suspected cases of acute poisoning, overdose, self-harm attempts, or environmental toxin exposure. Substances commonly assessed include therapeutic medications, illicit drugs, and environmental or occupational toxins. Screening relies on methods such as immunoassays for rapid detection and chromatographic or mass spectrometric techniques for confirmatory testing. Indications extend beyond emergency care to forensic investigations, occupational monitoring, and public health surveillance. However, this activity focuses on acutely ill patients rather than individuals exposed in the workplace or mandated to undergo rehabilitation testing.

Interpretation of results is challenged by variability in test availability, detection thresholds, accuracy, and clinical relevance. False positives, false negatives, and narrow detection windows may complicate clinical decision-making. Despite these limitations, toxicology screening informs diagnosis, guides therapeutic interventions, and aids in prognostication for poisoned or overdosed patients. Awareness of the technical constraints, clinical applicability, and potential medicolegal implications of screening is essential for appropriate ordering and interpretation with appreciation of false-positive and false-negative results.[1][2][3]

Etiology and Epidemiology

A substantial proportion of acute care encounters involve drug exposures, often identified primarily through patient history.[4] Alcohol intoxication remains the leading cause of substance-related visits. Encounters related to opioids, cocaine, marijuana, and synthetic drugs have increased significantly over the past 3 decades, with opioid-related mortality accounting for the majority of the rise over the past decade. Polysubstance use is common, with alcohol frequently coingested. Suicide attempts involving drugs and accidental ingestions also account for a considerable share of cases, with pediatric exposures posing particular concern in children younger than 5.[5][6]

The highest incidence of drug-related visits occurs among young adults aged 18 to 35, particularly in the context of illicit drug use. Opioid-related poisoning is more prevalent among men, most often in those aged 30 to 39.[7] Synthetic opioids and fentanyl analogues continue to present substantial clinical challenges, with rates showing partial stabilization but still accounting for a large proportion of overdose presentations. Coingestion with stimulants and benzodiazepines is frequently observed in opioid-related cases.[8] The evolving epidemiology of substance use underscores the need for continuous public health surveillance to inform both clinical practice and community-level strategies aimed at mitigating drug-related harm.

Specimen Requirements and Procedure

In acute illness, serum and urine samples are typically obtained for laboratory evaluation, with drug screening performed only when clinically indicated. Urine drug testing, widely applied in workplace monitoring, forensic analysis, and substance use treatment, follows standardized protocols designed to ensure specimen validity. A minimum urine volume of 30 mL is required for both initial and confirmatory testing, although some protocols, such as those of the Substance Abuse and Mental Health Services Administration, mandate 45 mL for split-sample procedures. Specimen temperature must be measured within 4 minutes of collection and fall within 32 to 38 °C (90-100 °F) to correspond to physiologic values.[9]

Urine pH should range from 4.5 to 8.5, though values up to 9.0 may occur naturally. Measurements outside this range raise suspicion of adulteration. Specific gravity between 1.003 and 1.030 and creatinine concentration at least 20 mg/dL are assessed to detect dilution or substitution, with additional assays for oxidants and adulterants included in certain protocols.[10] Chain-of-custody documentation and, when indicated, directly observed collection safeguard specimen integrity and maintain compliance with the Substance Abuse and Mental Health Services Administration and forensic standards.[11]

Diagnostic Tests

Toxicology screening has undergone substantial development over the past few decades. Early methodologies such as gas chromatography and radioimmunoassays have been largely supplanted in routine practice by newer immunoassays, including enzyme-linked sorbent immunoassay and cloned enzyme donor immunoassay. This transition reflects the greater speed, operational simplicity, and practicality of immunoassays in clinical settings.

Despite these advantages, immunoassays demonstrate reduced sensitivity and specificity compared to earlier techniques, are typically calibrated to detect individual substances rather than broad drug classes, and remain vulnerable to cross-reactivity with structurally related compounds. Comprehensive drug panels employing advanced analytical methods provide broader coverage but are limited by high cost, lengthy processing times, and delayed reporting, which can extend for several weeks, restricting their feasibility in most acute clinical contexts.[12][13][14]

No single analytical method provides comprehensive detection due to the diversity of potentially relevant drugs. Therefore, a multimodal strategy is required, ranging from inexpensive rapid spot tests to immunoassays and advanced chromatographic or mass spectrometric platforms.[15] Commonly employed techniques include thin-layer chromatography, high-performance liquid chromatography, gas chromatography, gas chromatography-mass spectrometry, liquid chromatography-mass spectrometry, and high-resolution mass spectrometry using time-of-flight or orbitrap systems.[16]

At present, gas chromatography-mass spectrometry remains the reference standard for confirmatory testing, although liquid chromatography-tandem mass spectrometry is increasingly applied in both clinical and forensic toxicology. Confirmatory testing is required in forensic contexts, including workplace drug testing. The appropriate selection of analytic methods and the accurate interpretation of results depend on a sound understanding of the pharmacology and pharmacokinetics of the substances under evaluation.[17]

Drug testing may be performed using urine, serum, breath, sweat, or saliva. Breath analysis is used almost exclusively to estimate alcohol concentration, whereas urine and serum testing remain the most widely used approaches in clinical practice.[18]

Urine Testing

Illicit drugs of abuse represent a major focus of toxicology screening, most commonly through urine testing. In the United States, 5 substances are traditionally targeted in routine urine drug screens—cocaine, amphetamines, marijuana, phencyclidine (also known as phenylcyclohexyl piperidine, PCP), and opioids. These agents were selected as priority targets by the National Institute on Drug Abuse to standardize screening for substances most frequently associated with misuse and public health burden.

Many assays also include benzodiazepines. Beyond the potential for false-positive or false-negative results, standard urine assays fail to detect several illicit substances. The epidemiology of drug use has changed substantially over the past decade, with increasing prevalence of synthetic cannabinoids, 3,4-methylenedioxymethamphetamine (commonly known as ecstasy), and chemical analogues of opioids and PCP, many of which are not identified by routine urine testing.

Additional drugs of misuse that are generally excluded from standard panels include ketamine, chloral hydrate, γ-hydroxybutyrate, psilocybin, and synthetic cathinones, often referred to as bath salts.[19][20] Most urine assays provide only qualitative results, reporting a positive or negative finding when a specific analyte is detected, without offering quantitative concentration data.

Serum Testing

Serum testing is commonly employed to detect over-the-counter drugs frequently implicated in intentional overdose. Standard assays measure acetaminophen, aspirin, salicylates, and ethanol, with some extended panels including tricyclic antidepressants and barbiturates. Unlike urine screening, serum testing is typically quantitative and provides blood concentration values that require interpretation in the context of reported timing and dose of ingestion. Serial measurements are often necessary when the clinical history is incomplete or unreliable. Although ethanol is reliably identified in alcohol assays, other toxic alcohols such as methanol, ethylene glycol, and isopropyl alcohol are not detected by standard screening methods.[21]

Testing Procedures

Several considerations guide the ordering of toxicology screening in clinical practice. Testing should be performed for clinical purposes unless a patient specifically requests evaluation for legal or forensic reasons, as in suspected cases of drug-facilitated sexual assault. In such instances, testing remains a component of the clinician's duty to the patient and is ethically permissible. Toxicology testing requested by or performed for the benefit of external parties, including law enforcement, is not permissible without patient consent. When a patient cannot provide consent, as frequently occurs in suspected drug intoxication, toxicology testing may be performed as a diagnostic tool solely for the patient's clinical benefit.

Exceptions exist in limited circumstances. A valid warrant permits testing even when not clinically indicated. Testing may also be justified when a legitimate public safety concern arises, provided it is ordered and disclosed in good faith. Such decisions are subject to judicial scrutiny, requiring clinicians to exercise careful judgment to balance patient welfare with public safety.

Results, Reporting, and Critical Findings

Urine toxicology tests are qualitative assays that identify the presence of multiple illicit drugs. Detection windows vary by substance, requiring careful interpretation and correlation with the clinical presentation. Certain drugs or their metabolites may be detectable long after intoxication, producing true positives that are no longer clinically relevant. Prolonged detection following use or resolution of effects is a common limitation of these tests.

Cocaine screening relies on the detection of the metabolite benzoylecgonine, which is measured with high specificity and minimal concern for false-positive or false-negative results. Although benzoylecgonine may remain detectable for up to 3 days after use, the principal clinical effects of cocaine generally subside within 6 to 12 hours. Amphetamine testing is more limited, as numerous medications—including antihistamines, decongestants, antidepressants, and acid-suppressing agents—can yield false-positive results. True amphetamine use is typically detected for 1 to 3 days. Marijuana assays are also susceptible to cross-reactivity, with common over-the-counter analgesics such as ibuprofen and naproxen occasionally producing false-positive results.

Screening for PCP is limited by the potential for false-positive results, most notably with ibuprofen, dextromethorphan, and tramadol. Urinary detection may persist for 1 to 2 weeks after use, well beyond the period of intoxication. Opioid screening is likewise problematic, as many opioids are not identified by standard assays, leading to a high rate of false-negative results. False-positive results have also been documented, particularly following ingestion of poppy seeds or quinolone antimicrobials.[22] When present, opioids are typically detectable for 1 to 4 days.

Benzodiazepine assays are among the least clinically informative. Although false-positive results occur, false-negative results are substantially more common because most immunoassays identify only the oxazepam metabolite. Diazepam undergoes metabolism to oxazepam and is, therefore, reliably detected, with potential persistence in the urine for up to 4 weeks. In contrast, benzodiazepines such as midazolam, lorazepam, and alprazolam metabolize to other products and are generally missed on routine screening.

Serum testing may provide greater insight into timing because results are quantitative rather than qualitative. Nevertheless, interpretation can be challenging, as concentrations may reflect rising or falling levels, and the pharmacokinetics and metabolism of many substances are unpredictable. Repeat sampling is often necessary to clarify trends.

Although several examples of false-positive and false-negative results have been described, no comprehensive list of cross-reacting substances exists. The table, Reports of False-Positive Results of Urine Drug Screens for Selected Formulary Agents, reproduced with permission, summarizes common pitfalls of drug screening based on several published reviews (see Image. Reports of False-Positive Results of Urine Drug Screens for Selected Formulary Agents).[23]

Clinical Significance

Toxicologic screening may inform both acute management and long-term treatment. However, urine and serum assays are subject to important limitations that reduce their overall clinical utility.

Positive drug screens in asymptomatic patients may represent the detection of metabolites or prior exposure, findings that often have no relevance for immediate management. In certain cases, positive results represent recent exposure in individuals whose tolerance blunts clinical presentation. Even when positive results align with the patient's presentation, they may still reflect earlier substance use and lead clinicians to assume a definitive diagnosis incorrectly. Conversely, negative screens cannot reliably exclude substance use due to limitations in assay sensitivity, detection windows, and metabolic variability.

Although urine testing rarely alters clinical management, serum toxicologic screening may provide clinically meaningful information in selected cases. Serum testing is essential in patients with suspected intentional ingestions, particularly for acetaminophen, where the availability of the antidote N-acetylcysteine makes early detection critical. Serum acetaminophen concentrations may provide the only evidence of acute poisoning in patients with early-stage toxicity and minimal clinical manifestations. Salicylate poisoning is another diagnostic challenge in which serum concentrations play an important role in guiding management.

Urine testing yields qualitative, presumptive results that require clinical interpretation. Serum testing provides quantitative, presumptive results that also require interpretation, and repeat sampling may be necessary in specific toxic exposures. All toxicologic screening must be interpreted in the context of the clinical presentation and should not be used as a routine exclusionary or confirmatory measure in suspected poisoning.[24]

Quality Control and Lab Safety

A quality management system (QMS) is essential for clinical and toxicology laboratories to ensure accurate, reliable, and legally defensible results that influence patient care, forensic determinations, and regulatory compliance.[25][26] The QMS integrates internal quality control (IQC), external quality assessment (EQA), and biosafety practices to maintain analytical precision and workplace safety.

The QMS provides a structured framework that minimizes error, ensures consistency, and upholds standards mandated by regulatory bodies, including the International Organization for Standardization (ISO) 15189, the College of American Pathologists (CAP) accreditation program, and the Occupational Safety and Health Administration (OSHA) guidelines. Through rigorous quality control, external validation, and safety protocols, the QMS preserves the integrity of laboratory results and safeguards personnel handling hazardous materials.[27][28]

IQC is a cornerstone of the QMS, performed with each analytical run to verify the performance of instruments, reagents, and assays across diverse analytical platforms. These platforms include immunoassays, enzyme-linked immunosorbent assays, thin-layer chromatography, high-performance liquid chromatography, gas chromatography, gas chromatography-mass spectrometry, liquid chromatography-mass spectrometry, and high-resolution mass spectrometry systems such as time-of-flight and orbitrap platforms.[29]

IQC involves calibration verification using certified reference materials, along with the analysis of control samples at low, medium, and high concentrations to monitor both precision and accuracy. Statistical process control tools, such as Levey-Jennings charts, are used to detect shifts or trends over time. Testing is suspended immediately when control values fall outside defined limits, and a structured root cause analysis is conducted to identify the source of the deviation. Corrective measures, including recalibration, reagent replacement, or system maintenance, are implemented and documented before testing is resumed. This process is essential for maintaining assay integrity and ensuring that results remain reliable and reproducible, a requirement in both clinical diagnostics and forensic toxicology.[30][31]

EQA complements IQC by providing an independent assessment of laboratory performance through blinded proficiency samples distributed on a scheduled basis. EQA enables laboratories to benchmark accuracy against peer institutions, uncover systematic errors not detected by IQC, and meet accreditation requirements such as ISO 15189 and CAP. Trend analysis of EQA data supports method validation, highlights recurrent issues, and promotes continuous quality improvement.[32] Active participation in EQA programs ensures compliance and reinforces confidence in a laboratory's ability to generate accurate, defensible results, particularly in forensic and clinical applications where precision is critical.[33]

Biosafety and safety practices are integral to the QMS, as toxicology laboratories routinely handle hazardous biological specimens and chemicals. Personnel must use personal protective equipment, including gloves, laboratory coats, and protective eyewear, with additional tools such as respirators or face shields when handling volatile solvents or high-risk materials. Environmental controls, including class II or higher biosafety cabinets for biological samples, chemical fume hoods for hazardous reagents, and adequate ventilation systems, reduce occupational exposure risks. All specimens are managed under universal precautions and treated as potentially infectious.

In forensic toxicology, strict chain-of-custody documentation, tamper-evident seals, and secure sample tracking are required to ensure legal defensibility. Samples are stored under controlled conditions, either refrigerated at 2 to 8 °C or frozen at −20 °C, depending on analyte stability, with restricted access to controlled substances in accordance with regulatory requirements.[34][35]

Waste management and spill response are essential components of laboratory safety. Biological waste is sterilized through autoclaving or chemical disinfection. Chemical waste is segregated by hazard class, such as flammable or corrosive. Puncture-resistant sharps containers are used for needles and glassware to prevent injuries. Spill response protocols include immediate containment, with biological spills decontaminated using disinfectants such as 10% bleach and chemical spills managed with specialized spill kits tailored to the specific hazard. These measures protect personnel and prevent contamination that could compromise analytical integrity.[36]

Ongoing, documented staff training ensures familiarity with QMS procedures, biosafety standards, emergency protocols, and regulatory updates. A structured incident reporting system promotes accountability by documenting and investigating issues such as control failures or safety breaches. Routine internal and external audits confirm compliance and highlight areas for improvement, reinforcing a culture of safety and quality. Compliance with international and national standards, including ISO 15189, CAP, and OSHA, is required to maintain accreditation and validate laboratory results. By integrating IQC, EQA, and comprehensive biosafety practices, the QMS ensures that clinical and toxicology laboratories deliver accurate, defensible, and safe results while protecting personnel and meeting regulatory obligations.[37]

Enhancing Healthcare Team Outcomes

Screening for toxic substances is a routine practice in most emergency departments, yet clinicians must recognize that results are not always immediately available, and early management frequently relies on clinical judgment. Toxicology testing may be requested for diverse purposes, including forensic investigations, suspected overdoses, illicit drug use, and cases of sexual assault. Informed consent is typically necessary, though testing may occur without consent if the patient is incapacitated, provided the procedure is performed in good faith for the patient’s benefit or mandated by legal authority.

Effective toxicology testing requires close collaboration between the laboratory and the healthcare team. Providing key clinical information ensures appropriate test selection and accurate interpretation of findings. Critical details include the suspected time and date of exposure, the timing of sample collection, relevant patient or witness history that may aid in toxin identification, and the patient’s clinical status at presentation. Supplying this context enables the laboratory to maximize both diagnostic value and clinical relevance, thereby supporting informed management decisions and improving patient outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Crouse JJ, Chitty KM, Iorfino F, White D, Nichles A, Zmicerevska N, Guastella AJ, Moustafa AA, Hermens DF, Scott EM, Hickie IB. Exploring associations between early substance use and longitudinal socio-occupational functioning in young people engaged in a mental health service. PLoS One. 2019;14(1):e0210877. [PMC free article: PMC6336340] [PubMed: 30653581]

2.

Gessner A, König J, Fromm MF. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin Pharmacol Ther. 2019 Jun;105(6):1386-1394. [PubMed: 30648735]

3.

Sluiter RL, Janzing JGE, van der Wilt GJ, Kievit W, Teichert M. An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care. Pharmacogenomics J. 2019 Oct;19(5):480-489. [PubMed: 30647446]

4.

Ayalew MB, Tegegn HG, Abdela OA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. Bull Emerg Trauma. 2019 Oct;7(4):339-346. [PMC free article: PMC6911719] [PubMed: 31857995]

5.

Vilaça L, Volpe FM, Ladeira RM. ACCIDENTAL POISONING IN CHILDREN AND ADOLESCENTS ADMITTED TO A REFERRAL TOXICOLOGY DEPARTMENT OF A BRAZILIAN EMERGENCY HOSPITAL. Rev Paul Pediatr. 2020;38:e2018096. [PMC free article: PMC6909246] [PubMed: 31778403]

6.

Madden MA. Pediatric Toxicology: Emerging Trends. J Pediatr Intensive Care. 2015 Jun;4(2):103-110. [PMC free article: PMC6513128] [PubMed: 31110859]

7.

Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):224-233. [PMC free article: PMC6034966] [PubMed: 29911818]

8.

Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021 Jul 01;34(4):344-350. [PMC free article: PMC8154745] [PubMed: 33965972]

9.

Raouf M, Bettinger JJ, Fudin J. A Practical Guide to Urine Drug Monitoring. Fed Pract. 2018 Apr;35(4):38-44. [PMC free article: PMC6368048] [PubMed: 30766353]

10.

Lin SY, Lee HH, Lee JF, Chen BH. Urine specimen validity test for drug abuse testing in workplace and court settings. J Food Drug Anal. 2018 Jan;26(1):380-384. [PMC free article: PMC9332641] [PubMed: 29389577]

11.

Dinis-Oliveira RJ, Vieira DN, Magalhães T. Guidelines for Collection of Biological Samples for Clinical and Forensic Toxicological Analysis. Forensic Sci Res. 2016;1(1):42-51. [PMC free article: PMC6197137] [PubMed: 30483610]

12.

Patlewicz G, Richard AM, Williams AJ, Grulke CM, Sams R, Lambert J, Noyes PD, DeVito MJ, Hines RN, Strynar M, Guiseppi-Elie A, Thomas RS. A Chemical Category-Based Prioritization Approach for Selecting 75 Per- and Polyfluoroalkyl Substances (PFAS) for Tiered Toxicity and Toxicokinetic Testing. Environ Health Perspect. 2019 Jan;127(1):14501. [PMC free article: PMC6378680] [PubMed: 30632786]

13.

Shahi S, Özcan M, Maleki Dizaj S, Sharifi S, Al-Haj Husain N, Eftekhari A, Ahmadian E. A review on potential toxicity of dental material and screening their biocompatibility. Toxicol Mech Methods. 2019 Jun;29(5):368-377. [PubMed: 30642212]

14.

Thomas AA, Dickerson-Young T, Mazor S. Unintentional Pediatric Marijuana Exposures at a Tertiary Care Children's Hospital in Washington State: A Retrospective Review. Pediatr Emerg Care. 2021 Oct 01;37(10):e594-e598. [PubMed: 30601351]

15.

Rygaard K, Pan M, Nielsen MKK, Dalsgaard PW, Rasmussen BS, Linnet K. Overview of systematic toxicological analysis strategies and their coverage of substances in forensic toxicology. Anal Sci Adv. 2023 May;4(3-4):96-103. [PMC free article: PMC10989544] [PubMed: 38715924]

16.

Mahadevarao Premnath S, Zubair M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 11, 2024. Chromatography. [PubMed: 38261673]

17.

Mikel C, Pesce A, West C. A tale of two drug testing technologies: GC-MS and LC-MS/MS. Pain Physician. 2010 Jan-Feb;13(1):91-2. [PubMed: 20119467]

18.

Dolan K, Rouen D, Kimber J. An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug Alcohol Rev. 2004 Jun;23(2):213-7. [PubMed: 15370028]

19.

White J, Weinstein SA, De Haro L, Bédry R, Schaper A, Rumack BH, Zilker T. Mushroom poisoning: A proposed new clinical classification. Toxicon. 2019 Jan;157:53-65. [PubMed: 30439442]

20.

Nakhaee S, Naseri K, Mehrpour O. Toxic alcohol diagnosis and management: an emergency medicine review-comment. Intern Emerg Med. 2019 Oct;14(7):1183-1184. [PubMed: 30600525]

21.

Posin SL, Kong EL, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Mercury Toxicity. [PubMed: 29763110]

22.

Farley TM, Anderson EN, Feller JN. False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. BMJ Case Rep. 2017 Nov 23;2017 [PMC free article: PMC5720316] [PubMed: 29170178]

23.

Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. 2010 Aug 15;67(16):1344-50. [PubMed: 20689123]

24.

Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med. 2009 May 21;360(21):2216-23. [PubMed: 19458366]

25.

Allen LC. Role of a quality management system in improving patient safety - laboratory aspects. Clin Biochem. 2013 Sep;46(13-14):1187-93. [PubMed: 23648455]

26.

Smith JH, Horne JS. Quality management system in forensic science: An African perspective. Forensic Sci Int Synerg. 2024;8:100476. [PMC free article: PMC11070588] [PubMed: 38711931]

27.

Plebani M, Sciacovelli L. ISO 15189 Accreditation: Navigation Between Quality Management and Patient Safety. J Med Biochem. 2017 Sep;36(3):225-230. [PMC free article: PMC6287216] [PubMed: 30564060]

28.

Neuteboom W, Ross A, Bugeja L, Willis S, Roux C, Lothridge K. Quality Management in forensic science: A closer inspection. Forensic Sci Int. 2024 May;358:111779. [PubMed: 37479548]

29.

Gruber L, Hausch A, Mueller T. Internal Quality Controls in the Medical Laboratory: A Narrative Review of the Basic Principles of an Appropriate Quality Control Plan. Diagnostics (Basel). 2024 Oct 05;14(19) [PMC free article: PMC11475633] [PubMed: 39410627]

30.

Giannoli JM, Vassault A, Carobene A, Liaudet AP, Blasutig IM, Dabla PK, Lin J, Thomas A, Tesser Poloni JA, Meng QH, Amann EP., International Federation of Clinical Chemistry. Laboratory Medicine Task Force on Global Lab Quality TF-GLQ. Ensuring internal quality control practices in medical Laboratories: IFCC recommendations for practical applications based on ISO 15189:2022. Clin Chim Acta. 2025 Apr 15;571:120240. [PubMed: 40064457]

31.

Pradella M. Divergences between IFCC recommendations for internal quality control and ISO standards. Clin Chim Acta. 2025 Jun 15;574:120334. [PubMed: 40320161]

32.

Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem. 2011 Dec;57(12):1670-80. [PubMed: 21965556]

33.

Buchta C, De la Salle B, Marrington R, Albarède S, Badrick T, Bicker W, Bietenbeck A, Bullock D, Delatour V, Dequeker E, Flasch M, Geilenkeuser WJ, van Hellemond J, Huggett JF, Ianovska V, Kaiser P, Kammel M, Kessler A, Laudus N, Luppa PB, Morandi PA, O'Connor G, Panteghini M, Pezzati P, Rosendahl J, Sandberg S, Scheiblauer H, Skitek M, Spannagl M, Stavelin A, Thelen M, Unterberger U, Zeichhardt H, Restelli V, Perrone LA. Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratories. Clin Chem Lab Med. 2025 Apr 28;63(5):879-897. [PubMed: 39754494]

34.

Cornish NE, Anderson NL, Arambula DG, Arduino MJ, Bryan A, Burton NC, Chen B, Dickson BA, Giri JG, Griffith NK, Pentella MA, Salerno RM, Sandhu P, Snyder JW, Tormey CA, Wagar EA, Weirich EG, Campbell S. Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future. Clin Microbiol Rev. 2021 Jun 16;34(3):e0012618. [PMC free article: PMC8262806] [PubMed: 34105993]

35.

Jagtap GA, Badge A, Kohale MG, Wankhade RS. The Role of the Biosafety Cabinet in Preventing Infection in the Clinical Laboratory. Cureus. 2023 Dec;15(12):e51309. [PMC free article: PMC10823295] [PubMed: 38288229]

36.

Vijayan V, Sern BNB, Johnson B. Modified Efficient and Simple Method for Biological Spill Cleanup. Appl Biosaf. 2019 Sep 01;24(3):141-146. [PMC free article: PMC9134464] [PubMed: 36032338]

37.

Pillai SP, Fox E. Laboratory quality management system fundamentals. Front Bioeng Biotechnol. 2025;13:1578654. [PMC free article: PMC12133829] [PubMed: 40470502]

Disclosure: Pinaki Mukherji declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Zubair declares no relevant financial relationships with ineligible companies.

Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.